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Abstract  
Both isobaric tags for relative and absolute quantitation (iTRAQ) and label-free methods are 
widely used for quantitative proteomics. Here, we provide a detailed evaluation of these 
proteomics approaches based on large datasets from biological samples. iTRAQ-label-based 
and label-free quantitation were compared using protein lysate samples from non-infected 
human lung epithelial A549 cells and from cells infected for 24 h with human adenovirus type 3 
or type 5. Either iTRAQ-label-based or label-free methods were used, and the resulting samples 
were analyzed by liquid chromatography (LC) and tandem mass spectrometry (MS/MS). To 
reduce a possible bias from quantitation software, we applied several software packages for 
each procedure. ProteinPilot and ScaffoldQ+ software were used for iTRAQ-labeled samples, 
while Progenesis LC-MS and ProgenesisF-T2PQ/T3PQ were employed for label-free analyses. 
R2 correlation coefficients correlated well between two software packages applied to the same 
datasets with values between 0.48 and 0.78 for iTRAQ-label-based and 0.5 and 0.86 for label-
free quantitations. Analyses of label-free samples, showed higher levels of protein up- or down-
regulation in comparison to iTRAQ-labeled samples. The concentration differences were further 
evaluated by Western blotting for four down-regulated proteins. These data suggested that the 
label-free method was more accurate than the iTRAQ method.   
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1. Introduction 
Quantitative proteomics based on mass spectrometry (MS) is an important methodology for 
biological and clinical research allowing, e.g., the identification of functional modules and 
pathways, or the monitoring of disease biomarkers [1, 2]. Relative quantitation of two or more 
samples for studies of differential protein expression is of particular importance. Quantitative 
results can be gained using stable isotope labels or label-free methods [3-5]. In general, isotope 
labels offer higher reproducibility in quantitation, and label-free methods require highly 
reproducible LC-MS/MS platforms [3]. Several labeling methods based on heavy isotopes such 
as 2H, 13C, 15N, and 18O have been developed and allow relative quantitation using MS. In vivo 
metabolic labeling methods, such as stable isotope labeling by amino acids in cell culture 
(SILAC) were introduced for arginine [6], lysine [7], tyrosine [8] or leucine [9]. For direct labeling 
of proteins or peptides, two strategies are being generally used. Isotope coded affinity tag 
(ICAT) labeling allows enrichment and MS analysis of cysteine-containing peptides [10]. iTRAQ 
was developed for both relative and absolute quantitation using internal peptide standards [11]. 
The iTRAQ reagents react with primary amines of amino-termini or lysine residues, and hence 
label most peptides and proteins occurring in cells. Upon collision-induced dissociation (CID), 
iTRAQ reporter ions are released and their relative intensities are used for protein quantitation. 
In contrast to ICAT and SILAC, where two or three samples are compared, iTRAQ allows 
simultaneous labeling and quantitation of four or eight samples [11, 12]. By combining multiple 
samples in one run, the instrument time for analyses can be reduced, and variations between 
different LC/MS runs do not affect the results. Comparative studies for different isotope labels 
including differential gel electrophoresis (DIGE), ICAT and iTRAQ showed that iTRAQ is more 
sensitive than ICAT [13]. Another study compared iTRAQ-label and label-free methods, and 
identified 79 proteins with both methods [14], but it remains unclear which method is best suited 
for quantitative proteomics. However, a recent analysis of two Chlamydomonas reinhardtii 
strains by Wang et al., provided a substantial comparison between iTRAQ-based and label-free 
methods [15]. The results indicated that both methods were comparable although quantitation 
for spiked-in standards reached closer to the expected values in label-free quantitation 
 4 
experiments, and most significantly regulated proteins showed slightly higher changes by label-
free compared to iTRAQ-label based quantitation. 
High-throughput quantitative proteomics experiments produce large datasets. To quantify iTRAQ 
ratios, an array of bioinformatic tools was introduced, including ProQuant (Applied Biosystems), 
TandTRAQ [16], Multi-Q [17], Mascot 2.2 (Matrix Science, London, UK), ScaffoldQ+ (Sc+, 
http://www.proteomesoftware.com/) and Protein Pilot (PP) [18]. PP utilizes Paragon as a search 
algorithm. Unlike PP, Scaffold does not contain a search engine, but uses Bayesian statistics 
and search outputs, such as Mascot to estimate peptide and protein identification probabilities. 
Scaffold has recently been up-dated to the Sc+ version with enhanced features for iTRAQ 
quantitation. Although iTRAQ-labeling has been widely applied, there is an ongoing discussion 
about the accuracy of the deduced protein quantitations, particularly when sample mixtures are 
highly complex [19-21]. iTRAQ-labels typically reveal fold changes of less than 2 orders of 
magnitude [22], unlike microarrays, which can be utilized for expression profiling over 3 orders of 
magnitude. This may be perceived as a limitation of the iTRAQ-labeling method for quantitative 
proteomics. 
Label-free approaches can be applied for both shotgun and targeted proteomics [23]. Moreover, 
they are cost-effective and reproducible [24]. There are two general approaches for label-free 
quantitation, measurement of spectral peak intensities [25] and spectral counting [26]. Both 
approaches require extensive processing of raw LC/MS data, leading to high demands on the 
bioinformatic tools. Thus, multiple software packages are recommended for data analyses. For 
instance, Progenesis LC-MS (PL, Nonlinear Dynamics) uses vectors to match all experiments to 
one reference sample for easy comparison of results. Next, a global scaling factor for each LC-
MS run is estimated to normalize all runs. The peptide abundance is taken as the sum of the 
peak areas within the isotope boundaries while the protein abundance is the sum of the 
abundance of all peptides from one particular protein. Finally, the peak lists are exported in the 
mgf format and can be used for the Mascot search engine, and are later imported back into PL. 
In addition, the counting of spectrum-peptide matches is often not an accurate measure of 
protein abundance due to physicochemical properties of peptides and the local chemical 
environment [27, 28]. To overcome a bias of MS/MS spectral counting, Lu et al. developed a so 
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called ‘Absolute Proteomics Expression’ counting method by introducing correction factors to 
predict detection rates of peptides [29]. More recently, Grossmann et al. refined a procedure for 
label-free quantitation by selecting the top N most prevalent precursor ions per protein (TNPQ), 
where N is equal to 2 or larger [30].  
In this study, we compared the iTRAQ-labeling method with the label-free method in complex 
samples from human lung adenocarcinoma cells infected with human adenovirus type 3 (HAdV-
B3) or type 5 (HAdV-C5). HAdVs are significant pathogens causing respiratory disease, 
gastroenteritis, acute hemorrhagic cystitis, meningoencephalitis or conjunctivitis [31, 32]. HAdVs 
are widely used and the most extensively studied viruses for gene delivery/therapy applications 
[33-36]. HAdV-C5 belongs to the best-studied viruses. It binds to the coxsackie and adenovirus 
receptor (CAR) [37, 38], internalizes by receptor-mediated endocytosis and activates its 
uncoating program at the cell surface [39, 40]. For infection of polarized cells, these viruses use 
cytokine-controlled receptor expression on the apical surface [41], and deliver their DNA 
genome by uncoating at the nuclear pore complex [42]. HAdV-B3 is a representative of the 
species B types that utilize CD46 and/or desmoglein 2 (DSG2) as attachment receptors [39, 43, 
44]. The underlying complexity of host factors controlling virus entry and infection is however 
incompletely understood [45]. Accurate analyses of global protein expression patterns in 
infected cells can contribute to a better understanding of essential virus–host interactions.  
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2. Methods 
Cells, virus and cell lysate preparation  
Human A549 lung adenocarcinoma epithelial cells were cultured in Dulbecco’s modified Eagles 
medium (Sigma) supplemented with 8% fetal bovine sera. A549 cells were infected with HAdV-
B3 or HAdV-C5 using a multiplicity of infection (MOI) of 200 infectious virus particles/cell. Non-
infected cells (ctrl) and HAdV-B3/C5-infected-cells were harvested at 24 hours (h) post infection 
(p.i.) with biological duplicates for each condition. The cells were washed twice in PBS by 
centrifugation. The cell pellets were then resuspended in lysis buffer containing 10 mM Hepes 
pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor 
cocktail (Roche) with sonication. Non-solubilized material was removed by centrifugation at 
16,000 × g for 20 minutes (min). The proteins contained in the supernatant were precipitated by 
addition of TCA to 20% and twice washed with 100% acetone. Finally, the proteins were 
solubilized in 0.5 M triethylammonium bicarbonate pH 8.5 plus 0.2% SDS, 1 M urea and 15% 
methanol. Protein concentrations were measured by the Qubit method (Invitrogen). For 
downstream analysis by LC-MS/MS, 30 µg of individual protein samples were used.  
 
Protein digestion, iTRAQ 8plex labeling, and chromatography  
For these experiments, 30 µg proteins of each sample were reduced in 2 mM of TCEP at 37°C 
for 1 h and the cysteine residues were blocked in 10 mM MMTS at room temperature for 15 min 
followed by trypsin digestion (modified trypsin, Promega) at a protease:protein ratio of 1:12.5 
(w/w) at 37°C for 8-10 h. iTRAQ-8plex labeling reagents (Applied Biosystems) were added to the 
peptide samples, which were incubated at room temperature for 140 min. The reaction was 
stopped by addition of 10 mM KH2PO4, 25% ACN, pH 2.6 (solvent A), followed by centrifugation 
at 16,000 × g for 10 min to remove the aggregated proteins. The digested protein samples were 
separated by using multidimensional liquid chromatography. In the first dimension, the peptide 
mixtures were fractionated using a SCX column (Polysulphoethyl A, 2.1 mm inner diameter, 
200 mm length, 300 Å pore size, 5 µm particle size, PolyLC Inc.). A linear binary gradient from 
solvent A (10 mM KH2PO4, 25% ACN, pH 2.6) to solvent B (10 mM KH2PO4, 0.35 M KCl, 25% 
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ACN, pH 2.6) was applied: 0% to 5% solvent B in 15 min, 5% to 35% B in 35 min, and 35% to 
100% B in 10 min. The entire run lasted 90 min, and 27 SCX fractions were collected. These 
fractions were vacuum-dried and redissolved in 0.1% TFA, 5% ACN. Based on the SCX 
chromatograms, the 27 SCX fractions were combined into 8 pools. All pools were further 
desalted by Sep-Pak C18 columns (Waters).  
Next, the pooled SCX fractions were automatically injected by a Famos autosampler and 
separated by an UltiMate capillary LC system (Dionex/LC Packings) and loaded onto a C18 
PepMap main column (75 µm ID, 150 mm length, 100 Å pore size, 3 µm particle size; Dionex) 
using a linear binary gradient (solvent A: 0.1% TFA; solvent B: 0.1% TFA, 80% ACN). HPLC 
linear gradients were increased by solvent B from 0% (10 min) to 50% (100 min) and from 50% 
to 100% (112 min). The peptides eluting from the LC column were then mixed with 3-4 mg/ml of 
CHCA matrix (Bruker Daltonics) in 0.1% TFA, 70% ACN containing internal neurotensin peptide 
(Sigma), and were automatically deposited onto an Opti-TOF® LC MALDI plate (Applied 
Biosystems) by using a Probot spotting device. Mass spectrometric analysis was conducted with 
a 4800 MALDI-TOF/TOF instrument (Applied Biosystems). 
 
Sample preparation and chromatography for label-free experiments 
For the label-free approach, 30 µg proteins for each replicate were reduced with 5 mM of TCEP 
at 37°C for 1 h and blocked with 10 mM iodoacetamide at room temperature for 30 min followed 
by trypsin digestion at 37°C for 8-10 h. The trypsin digestion was stopped by adding 5% TFA 
and the pH value was adjusted by 10 mM KH2PO4, 25% ACN, pH 2.6. The aggregated proteins 
were removed by centrifugation at 16,000 × g for 10 min. The protein digests were purified by 
using Sep-Pak C18 columns (Waters). The desalted peptides were vacuum-dried and dissolved 
in 0.2% formic acid and 3% ACN. The samples were injected into an Eksigent-nano-HPLC 
system (Eksigent Technologies, Dublin CA, USA) by an autosampler and separated on a self-
made RP tip column (75 µm × 80 mm) packed with C18 material (3 µm, 200 Å, AQ, Bischoff 
GmbH, Leonberg, Germany). The column was equilibrated with 97% solvent A (A: 1% ACN; 
0.2% formic acid in water) and 3% solvent B (B: 80% ACN, 0.2% formic acid in water). Peptides 
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were eluted using the following gradient: 0-50 min, 3-30% B; 50-58 min, 30-50% B, and 58-
60 min, 50-97% B at a flow rate of 0.2 µl/min. 
 
Mass spectrometry analysis 
Mass spectrometric analysis of the iTRAQ-labeled samples was performed on a 4800 MALDI-
TOF/TOF instrument equipped with a 355 nm Nd:YAG laser. Mass spectra were acquired in 
positive reflectron mode in the mass range from m/z 850 to 4,000, with a focus mass of m/z 
2,100. They were generated by accumulating data from 600 laser pulses, and they were 
internally recalibrated based on the molecular mass of the neurotensin peptide. The ten most 
intensive peptide ion signals showing a S/N ratio > 100 were subjected to MS/MS acquisition. 
Peptide CID was conducted at collision energy of 1 kV and at a gas pressure of approximately 
2.5 x 10-6 Torr.  
For the label-free approach, high accuracy mass spectra were acquired on an LTQ-ICR-FT-Ultra 
mass spectrometer (Thermo Scientific, Bremen, Germany) in the mass range of 300-2,000 m/z 
and at a target value of 1x106 ions and a resolution of 100,000 at m/z 400. Up to five data 
dependent MS/MS were recorded in parallel in the linear ion trap from the most intense ions with 
charge states 2+ or 3+ using collision induced dissociation. Target ions already selected for 
MS/MS acquisition were dynamically excluded for 120 seconds. Three independent LC/MS runs 
were performed for each sample. 
 
Database searches and quantitative proteome analysis  
Both PP and Mascot search engines were used for protein identification from iTRAQ data 
acquired on the MALDI-TOF/TOF instrument. Only Mascot was utilized to identify proteins from 
data acquired on the LTQ-FT-ICR instrument for label-free quantitation. For the analysis with PP 
v3.0 (Applied Biosystems), the acquired data was directly fetched from the Oracle database and 
searched with the Paragon algorithm.  For the analyses with Mascot, peak lists (mgf files) were 
generated using Mascot Distiller software v2.3 (Matrix Science Ltd., London, UK). The same 
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database, which contains a non-redundant protein database for both human and HAdVs 
proteins (www.uniprot.org) and a few of HAdV entries derived from NCBI, was applied for both 
PP and Mascot searches. The combined database contains 41,135 entries in total including the 
concatenated reversed decoy entries, which were added in order to estimate the protein FDR. 
The FDR was calculated according to [46].  
In Mascot searches, tolerances of 25 ppm for peptide masses and 0.25 Da for fragment ions 
were specified for data obtained by using the MALDI-TOF/TOF instrument. In case of data 
obtained by LTQ-FT-ICR analyses, tolerances of 5 ppm for peptides and of 0.6 Da for fragment 
ions were used. In all searches, carbamidomethylation or MMTS modification of cysteine 
residues was selected as fixed modifications and oxidation of methionine was considered as 
variable modification. To obtain a protein FDR below 5%, a Mascot ion score ≥ 30 for peptide 
identifications was required.  
 
Software used for protein quantitation 
PP and Sc+ (Proteome Software) were used for protein quantitation of iTRAQ-labeled samples. 
For PP, bias and background correction was applied and biological modifications were allowed. 
To obtain a protein FDR below 5%, protein identifications were filtered with PP score ≥ 1.3 
(equivalent to 95% confidence). PP analysis provided both protein identification and quantitation 
results. In contrast, we only used the protein identification feature from Mascot searches and 
applied the quantitation feature from Sc+. To improve reliability and confidence of protein 
quantitation, all precursor ion signals showing an intensity ≤ 50 were discarded before the data 
were imported into Sc+. We used two rather different software products for the comparison of 
the iTRAQ data also to investigate the effect of lower scoring peptide assignments on protein 
quantitation. PP includes peptides with relatively low scores in protein quantitation, while Sc+ is 
very stringent and takes only confident identifications into account for quantification of proteins. 
The quantitative analyses for the label-free approaches were performed by using the 
commercial PL software (Nonlinear Dynamics) as recommended by the vendor or the 
Progenesis feature data export was combined with the emerging “high flyer” strategy to quantify 
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proteins based on LC-MS signals. The idea of this strategy termed ProgenesisF-T2PQ (PF2) or 
ProgenesisF-T3PQ (PF3) [30] is that irrespective of how many peptides are found for one 
particular protein, only the most intense (n) precursor signals are used for protein quantitation. 
We adapted this method referred to as PF2 or PF3, respectively, based on the aligned 
Progenesis feature map by averaging the top N normalized volumes of features from the same 
protein. For the Progenesis analysis, which served also as the base for the ProgenesisF-
T2(3)PQ, the raw files were imported and the automatic choice for the reference run for the 
aligning was accepted. For each file, we seeded manually three to five vectors before automatic 
aligning to give the algorithm a good starting point. The aligned LCMS map was filtered with 
respect to the retention time and only the relevant part of the gradient was retained for 
quantitation. The identification results were filtered with the same ion score >= 30. Conflicting 
features were not used in quantitation.  
To calculate the log2 ratio for proteins, in the first stage we ranked features of one protein 
according to their mean abundance from the two biological replicates. Then, the top2 or top3 
features were averaged for each condition (HAdV-B3/C5-infected and non-infected) to get the 
quantitative value for each protein for each condition. Next we calculated the log2 ratio for each 
protein. Proteins with log2 ratios either ≥ 0.6 or ≤ -0.6 were considered to be differentially 
expressed. No t-test or statistical analysis was applied. 
 
Western blot analysis  
40 - 60 µg/lane of biological replicate A549 cell lysates including non-infected and HAdV-B3/C5-
infected cells were separated on 10 - 15% SDS-PAGE and blotted onto Immobilon™ PVDF 
transfer membranes (Millipore) using the semidry transfer system (Biorad). The rabbit anti-
human Gal1 and Gal3 antibody were generous gifts from Prof. Walter Nickel (University of 
Heidelberg, Germany). The mouse monoclonal antibody with specificity for anterior gradient 
protein 2 (AG-2, cat: sc-101211), and the goat polyclonal antibody with specificity for 4F2 cell-
surface antigen heavy chain (CD98, cat: sc-31251) were purchased from Santa Cruz 
Biotechnology Inc. The mouse anti-α-tubulin monoclonal antibody (DM1A) was purchased from 
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Sigma. All primary antibodies were diluted 1:1,000, except for DM1A, which was diluted 1:5,000. 
Unconjugated rabbit anti-goat IgG was diluted 1:3,000 (cat: G 4018, Sigma), and secondary 
HRP conjugated anti-mouse antibody (cat: NA931V, GE Healthcare) and anti-rabbit antibody 
(cat: NA934V, GE Healthcare) were used at a 1:3,000 dilution. Signal detection was performed 
in the chemiluminescence scanning mode of Image reader LAS 3000 (FUJIFILM Science Lab), 
and signal quantitation was performed using ImageGauge version 3 (FUJIFILM Science Lab).  
 12 
3. Results 
Workflow for quantitative proteomics using iTRAQ-based and label-free methods  
Two independent workflows for iTRAQ and label-free analyses were used with lysates of non-
infected and HAdV-B3- or HAdV-C5-infected A549 cells (Fig. 1). For the iTRAQ-labeled 
samples, we used PP and Sc+ software, and for the label-free samples, PL and ProgenesisF-
T2PQ (PF2) and ProgenesisF-T3PQ (PF3) software. For PP, 1,538 proteins were commonly 
quantified for HAdV-B3- and HAdV-C5-infected compared with non-infected cells (Tab 1), and a 
false discovery rate (FDR) for protein identification of 1.89% was indicated. For Sc+, the 
numbers of quantified proteins were below those from PP analyses with 1,340 commonly 
quantified proteins. For the Sc+ output, the FDR was zero. Together, these results indicated 
high levels of protein identification reliability.  
 
Correlation analyses for iTRAQ quantitation using PP and Sc+ software 
We performed ratiometric analyses of protein abundance between infected and non-infected 
cells to estimate the steady state of the cellular and viral proteome 24 h post infection when 
most of the viral proteins are expressed and the infection progresses towards the lytic phase 
[47]. First, we examined the reproducibility of two biological replicates from iTRAQ analyses 
quantified by PP and Sc+. By PP analyses, the squared Pearson correlation analysis revealed 
an R2 of 0.55 for HAdV-B3-infected cells, and an R2 of 0.76 for HAdV-C5-infected cells, 
respectively (Fig. 2A). By Sc+ analyses, the R2 coefficient was 0.49 for HAdV-B3-infected cells 
and 0.69 for HAdV-C5-infected cells, respectively, (Fig. 2B). The R2 Pearson correlations 
between PP and Sc+ were 0.7 for HAdV-B3, and 0.71 for HAdV-C5-infected cells (Fig. 2C). This 
indicated good reliability of both software tools, independent of the algorithm or search engine 
used for quantitation. These data also showed that the expression changes were more 
pronounced by Sc+ than PP analyses, as indicated by the slope values, which are smaller than 
1 in the Sc+ versus PP plots for HAdV-B3 and HAdV-C5 (Fig. 2C, red and black, respectively). 
This may be due to the fact that PP is also taking lower confident peptides into account for 
quantitation, while for Sc+ only high confidence peptide assignments are used for quantitation.  
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Importantly, most of the proteins quantified by Sc+ were also found by using PP (Tab. 2, 
STable 1 page 82-119). We quantified 1,267 and 1,263 proteins in common for both PP and Sc+ 
in HAdV-B3 and HAdV-C5-infected cells, respectively. The ratios of most quantified proteins 
were similar for PP and Sc+. For 65.5% of the proteins (827 out of 1,263) from HAdV-B3-
infected cells the ratios between PP and Sc+ had variations of about 20%, and for HAdV-C5-
infected cells, 64.6% (819 out of 1,267 proteins) had 20% variations.  
It is of note that viral proteins were exclusively detected in infected but not in non-infected cells. 
The up-regulated proteins consisted of viral and cellular proteins in both, PP and Sc+ analyses.  
When using PP, 37 proteins were found up-regulated with a threshold of 0.6 (log2 ratio 
equivalent to 1.5 fold changes) in HAdV-B3-infected cells, and 51 proteins were down-regulated 
in these cells (STable 2). Likewise, for HAdV-C5-infected cells, 33 proteins were up-regulated 
and 20 proteins were down-regulated. Within Sc+, 31 proteins were found up-regulated and 50 
proteins were down-regulated in HAdV-B3-infected cells, while 23 proteins were up-regulated 
and 25 proteins were down-regulated in HAdV-C5-infected cells. Altogether, 74 proteins were 
found up- or down-regulated with both programs in HAdV-B3-infected cells, and 40 proteins 
changed by more than 1.5 fold by both analysis programs for HAdV-C5-infected cells. Twelve 
and five proteins were single hit detections with PP or Sc+ in HAdV-B3-infected cells, and 
eighteen and nine viral proteins in HAdV-C5-infected cells. These differences are likely due to a 
different scoring algorithms used by the respective software programs.  
Ambiguous results between PP and Sc+ analyses were obtained for one of 1,263 quantified 
proteins in HAdV-B3-infected cells, and two of 1,267 proteins in HAdV-C5-infected cells 
(STable 2). For HAdV-B3, the ambiguously classified protein was eukaryotic translation initiation 
factor 3 subunit F (EIF3F, O00303), which had a log2 ratio of -1.12 with PP and -0.6 with Sc+. 
These differences were likely due to the filtering parameters of PP and Sc+. In the Sc+, both ion 
precursors and their MS/MS fragmentations are used for protein quantitation while in the PP 
only one ion precursor and its MS/MS fragmentation is considered. For EIF3F the two ion 
precursors had different values explaining the discrepancy between PP and Sc+. Similarly, two 
different precursors were used for PP quantitation in HAdV-C5-infected cells, and one precursor 
ion was taken into account for Sc+ quantitation in the case of sterol-4-alpha-carboxylate 3-
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dehydrogenase, (NSDHL, Q15738), which was scored as 1.1 of log2 ratio change in PP, and 
without change in Sc+. The second protein misclassified in HAdV-C5 was DNA polymerase 
epsilon subunit 4. PP analyses showed up-regulation by 0.85 of log2 while Sc+ indicated down-
regulation by -0.90 (STable 2). Unlike the two cases described above, both precursor ions were 
scored in PP and Sc+ quantitation but two precursor ions had low intensity of reporter ions, 
which created a bias in the PP quantitation, and hence caused the difference in software output.  
 
Label-free quantitation by PL, PF2 and PF3 quantitation software yields similar results 
For analyses of the label-free data, we also utilized several quantitation algorithms, including PL, 
and PF2 and its variant PF3. These programs commonly use Mascot as search engine for 
protein identification, but apply different algorithms for protein quantitation. With PL quantitation, 
we obtained results for 661 and 660 proteins in HAdV-B3 and HAdV-C5-infected cells, 
respectively. Reproducibility of two biological replicates was lower in HAdV-B3-infected cells 
(Pearson correlation R2 of 0.50) than in HAdV-C5-infected cells (R2 value of 0.80) as shown in 
Fig. 2D and STable 1. Among the quantified proteins, 48 were found up-regulated (≥ 0.6 log2 
ratio) in HAdV-B3-infected cells, including 16 viral proteins, and 39 proteins were down-
regulated (≤ -0.6 log2 ratio) (STable 2). For HAdV-C5-infected cells, 59 proteins were found to be 
up-regulated, including 17 viral proteins, and five proteins were down-regulated.  
The label-free data were also quantified by using our own high-flyer strategy PF2 and PF3. With 
PF2, 439 proteins for both HAdV-B3- and HAdV-C5-infected cells were quantified with good 
correlation coefficients in replica tests with R2 of 0.62 for HAdV-B3-infected cells, and 0.86 for 
HAdV-C5-infected cells (Fig. 2E and STable 1). Proteins that were either down-regulated (≤ -0.6 
log2 ratio) or up-regulated (≥ 0.6 log2 ratio) are presented in STable 2. Using PF2, 42 proteins 
were found to be up-regulated in HAdV-B3-infected cells, including 16 viral proteins, and 37 
proteins appeared as down-regulated. In HAdV-C5-infected cells, 54 proteins were found to be 
up-regulated, including 17 viral proteins, and seven proteins were down-regulated. 17 of the 
regulated proteins were found in both HAdV-B3- and HAdV-C5-infected cells.  
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Using PF3, we quantified 347 proteins in both, HAdV-B3- and HAdV-C5-infected cells 
(STable 1). Comparison of the data obtained with PF2 and PF3 revealed a squared Pearson 
correlation R2 of 0.97 for proteins from HAdV-B3-infected cells and R2 of 0.99 for proteins of 
HAdV-C5-infected cells (SFig. 1 and STable 1), indicating excellent correlation between PF2 and 
PF3.  Since PF2 had higher sensitivity than PF3, we subsequently used PF2 for label-free 
analyses. 
When we compared the squared Pearson correlation between PL and PF2 data, the resulting 
correlation R2 amounted to 0.93 for proteins of HAdV-B3-infected cells, and 0.96 for proteins of 
HAdV-C5-infected cells for 439 common proteins (Fig. 2F and STable 1 page 34-47). In HAdV-
B3-infected cells, 78, including 16 viral proteins, were up or down-regulated (0.6 log2 ratio cut-
off), and all of them with parallel trends. In HAdV-C5-infected cells 57 proteins were up- or down-
regulated (0.6 log2 ratio cut-off), including 16 viral proteins. These results indicated a high 
reproducibility of biological replicates analyzed by either PL or PF2 software. In summary, the 
differential expression patterns of cellular proteins found in HAdV-B3/C5-infected cells compared 
to non-infected cells correlated well when analyzed by the two programs. The differences in 
protein abundance between HAdV-B3- and HAdV-C5-infected cells is likely due to the different 
nature of the viruses rather than due to different analysis software or algorithms.  
 
Correlation analysis for iTRAQ-based versus label-free quantitation 
We next addressed the level of correlation between iTRAQ-label and label-free methods by 
comparing four data sets, PP against PL, PP against PF2, Sc+ against PL, and Sc+ against PF2 
(Fig. 3A-D). For iTRAQ-labeled samples from HAdV-B3- or HAdV-C5-infected cells we found a 
correlation coefficient R2 between PP and PL of 0.48 and 0.73, considering 564 and 569 
commonly quantified proteins, respectively (Fig. 3A and STable 1 page 1-18). Among these, 23 
proteins, including 12 viral proteins were up or down-regulated in HAdV-B3-infected cells with 
both, iTRAQ-8plex (by PP) and label-free (by PL) procedures, and 18 proteins in HAdV-C5-
infected cells (STable 2). We noticed that all proteins above a cut-off of 0.6 log2 ratio had a 
similar pattern of either up or down regulation. However, the fold change for the same proteins 
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quantified by label-free methods generally gave higher values than quantified by the iTRAQ-
label method. This observation was confirmed by slope values of 1.06 for proteins of HAdV-B3-
infected cells and 1.20 for proteins of HAdV-C5-infected cells (Fig 3A). This is illustrated for 
instance with the viral proteins from these samples (STable 2).   
Most of the cellular proteins with expression changes above the 0.6 log2 ratio cut-off revealed 
the same trend with both analysis programs, except two proteins, P62633 (cellular nucleic acid-
binding protein, CNBP) and P68036 (ubiquitin-conjugating enzyme E2 L3, UBE2L3).  The former 
was down-regulated according to the iTRAQ ratio (by -0.74 log2 ratio) but up-regulated in the 
label-free analysis (by 1.01 log2 ratio) in HAdV-B3-infected cells. The latter was up-regulated 
according to the iTRAQ analysis (by 0.88 log2 ratio), and down-regulated according to the label-
free quantitation (by -1.34 log2 ratio) in HAdV-B3-infected cells. In these cases, precursor ions 
resulted in low intensities and only one precursor ion was used for quantitation. In these two 
cases, it is difficult to judge which quantitation method is more reliable.  
The squared Pearson correlations of PP (iTRAQ-label) and PF2 (label-free) gave rise to higher 
R2 values compared to the PP and PL pair, that is 0.69 for HAdV-B3 from 406 proteins, and 0.78 
for HAdV-C5 from 410 proteins (Fig. 3B and STable 1 page 58-70). Among these, 22 and 18 
proteins were up or down-regulated (log2 ratio ≥ 0.6) in both iTRAQ-8plex (PP) and label-free 
analyses (PF2) for HAdV-B3- and HAdV-C5-infected cells, respectively (STable 2). Similar to the 
findings in the comparison PP against PL, fold changes of protein expression levels were more 
pronounced for the data derived by PF2 compared to PP, as illustrated by slope values of 1.22 
and 1.35 for proteins of HAdV-B3- and HAdV-C5-infected cells, respectively.   
We noticed that the iTRAQ approach quantified a larger number of proteins than the label-free 
method, most likely due to the pre-fractionation of the iTRAQ- sample. Since the sample 
fractionation approaches were different for the iTRAQ samples and the label-free samples, 
certain peptides may have not been recovered or have missed the threshold of detection in only 
one of the two approaches. However, to evaluate the accuracy of the iTRAQ and label-free 
quantitation approaches, we only compared proteins commonly quantified by both methods.  
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For Sc+ against PL, the squared Pearson correlation R2 was 0.37 for 532 proteins in HAdV-B3-
infected cells, and 0.60 for 535 proteins in HAdV-C5-infected cells (Fig. 3C, STable 1 page 18-
34). In both iTRAQ-8plex (Sc+) and label-free (PL) samples from HAdV-B3- and HAdV-C5-
infected cells 20 and 9 proteins were either up or down-regulated (0.6 log2 ratio), respectively 
(STable 2). The slope values of PL against Sc+ were 1.11 for HAdV-B3 and 1.28 for HAdV-C5-
infected cells (Fig. 3C), indicating that alterations in protein abundance due to infection were 
more pronounced in the label-free approach in comparison to the iTRAQ-labeling method.  
The R2 Pearson correlation of Sc+ against PF2 was 0.54 for 394 proteins in HAdV-B3, and 0.71 
for 396 proteins in HAdV-C5-infected cells (Fig. 3D, STable 1 page 70-82). For HAdV-B3-
infected cells, 13 and 9 proteins from both infections were changed (cut-off 0.6 log2 ratio) in both 
iTRAQ-8plex (Sc+) and label-free (PF2) analyses (STable 2). Most of the regulated commonly 
identified proteins were detected in the label-free approach analyzed with PF2 (STable 2). The 
slope values of PF2 against Sc+ were 1.30 for HAdV-B3-, and 1.59 for HAdV-C5-infected cells 
(Fig. 3D). Together, the results confirmed that quantitation of proteins with the label-free method 
yielded higher expression changes than the iTRAQ-labeling quantitation for the same proteins.   
In summary, we found 12 and 17 viral proteins to be up-regulated by more than 0.6 log2 ratio in 
HAdV-B3- and HAdV-C5-infected-cells, respectively (Fig. 4A and B). In most cases, the label-
free approach revealed a higher expression change of viral proteins than the iTRAQ method. 
Robust expression changes were also observed for 17 cellular proteins in HAdV-B3-infected 
cells (Fig. 4C), while three proteins showed inconsistent patterns in iTRAQ-label and label-free 
quantitations. These included cellular nucleic acid-binding protein (CNBP1), ubiquitin-
conjugating enzyme E2L3 (UbcH7), and nuclease-sensitive element-binding protein 1 (YBX1). In 
HAdV-C5-infected cells, only two common up or down-regulated cellular proteins were observed 
at 24 h post infection, sequestosome-1 (SQSTM1, also known as ubiquitin binding protein p62) 
involved in the NFkB pathway [48] and heat shock 70 kDa protein 1A/1B (HSPA1A), an ATP-
dependent molecular chaperone (STable 2).  
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Western blot quantitation for four up or down-regulated cellular proteins in HAdV-B3- or 
HAdV-C5-infected cells  
To validate the iTRAQ-label and label-free quantitation results, we analyzed four down-regulated 
cellular proteins by Western immunoblotting, including galectin-1 (LGALS1, or Gal1), galectin-3 
(LGAL3, or Gal3), Anterior gradient protein 2 homolog (AG2) and CD98 (SLC3A2), an activator 
of dibasic and neutral amino acid transporter in both HAdV-B3- and HAdV-C5-infected cells. 
Although Gal3 was quantified in the iTRAQ experiment, but was not detected with the label-free 
approach, it was included in the analyses since it belongs to the same class of lectins as Gal1 
and binds to galactose of a variety of glycoproteins and glycolipids [49]. In HAdV-B3-infected 
cells, Gal1 was found to be down-regulated in Western blots similar to the label-free analyses, 
while the down-regulation was less pronounced according to the iTRAQ method (Fig. 5A). In 
HAdV-C5-infected cells, Gal1 remained roughly constant in both iTRAQ-label and label-free 
quantitations, but was reduced by 1.47 log2 ratio in Western blots. Western blots revealed a 
stronger down-regulation of Gal3 compared to iTRAQ-label quantitation in HAdV-B3-infected 
cells, while the Gal3 levels in HAdV-C5-infected cells remained largely unaffected (Fig. 5B).  
Western blot analyses confirmed down-regulation of AG2 in HAdV-B3-infected cells, even more 
pronounced in label-free than iTRAQ quantitations (Fig. 5C). The fold change quantified by 
Western blot analysis was closer to label-free quantitation than to iTRAQ ratios. In HAdV-C5, 
AG2 was induced in both Western blots and label-free analyses, but not in iTRAQ. Likewise, 
Western blot quantitations for CD98 showed robust down-regulation, stronger than in label-free 
and even stronger than in iTRAQ samples (Fig. 5D).  In summary, the Western blot validations 
performed here support the notion that the protein ratios in complex mixtures are 
underestimated by the iTRAQ method.  
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4. Discussion  
Increasingly, label-free quantitative proteomic methods are considered as reliable and important 
tools to complement labeling methods, owing to compatibility with high-throughput and high 
speed as well as to improved reproducibility of pre-fractionation of complex peptide mixtures 
[50].  
Here, we performed iTRAQ experiments using a MALDI-TOF-TOF mass spectrometer and 
label-free experiments using an LTQ-FT-ICR instrument. For a comparison of protein 
quantification approaches, application of a single type of mass spectrometer would have been 
favorable. However, LTQ-FT-ICR instruments are not fully compatible with iTRAQ- analyses 
because iTRAQ-reporter ions, which have a small mass per charge ratio (m/z), tend to get lost 
during acquisition. Conversely, MALDI-TOF/TOF mass spectrometers are not commonly utilized 
for label-free protein quantification. Nonetheless, we analyzed iTRAQ-labeled samples from one 
experiment with a 4800 MALDI-TOF/TOF (ABI) and with an LTQ OrbitrapXL (Thermo Scientific) 
mass spectrometer. The results of this comparison of quite different MS platforms were highly 
similar with regard to iTRAQ ratios (data not shown). In principle, LTQ OrbitrapsXL have a 
similar performance to that of LTQ-FT-ICR instruments except that low mass ions including 
iTRAQ reporter ions can be detected by utilizing higher energy collisional dissociation.  
Our biological replicates for HAdV-B3- and HAdV-C5-infected cells showed fairly good 
correlations, in both iTRAQ-label-based and label-free quantitation, irrespective of the particular 
quantitation software or strategy used. With the same dataset obtained from iTRAQ 
experiments, PP searches resulted in 1,538 quantified proteins for HAdV-B3- and 1,548 proteins 
for HAdV-C5-infected cells with ≥ 95% protein confidence (1.89% FDR), while Sc+ using the 
Mascot search engine showed 1,340 and 1,343 quantified proteins for HAdV-B3-and HAdV-C5-
infected cells, respectively, on peptide level of an ion score ≥ 30 (resulting in 0% FDR). Among 
these, 1,263 proteins in HAdV-B3- and 1,267 proteins in HAdV-C5-infected cells were commonly 
quantified by Sc+ and PP. The intersection could therefore be used to correlate the quantitative 
results. In the label-free method, PL quantified 661 proteins in HAdV-B3- and 660 proteins in 
HAdV-C5-infected cells, while PF2 quantified 439 proteins in both HAdV-B3- and HAdV-C5-
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infected cells. The reduction to 439 proteins can be explained by the fact that the PF2 method 
requires at least two peptides per protein. All proteins, which were quantified by PF2, were also 
quantified by PL. In this study, the peptide complexity in the iTRAQ-label approach was reduced 
with a pre-fractionation step by using SCX-HPLC prior to LC-MS/MS, while pre-fractionation of 
peptides in the label-free method was not considered prior to LC-MS/MS. Therefore, the number 
of proteins quantified by the label-free method was smaller than in the fractionated iTRAQ 
samples.  
Changes of differentially expressed proteins were generally similar for both iTRAQ and label-free 
methods, either up or down-regulated. This indicates that ratiometric analyses by both iTRAQ 
and label-free quantitation are reliable. However, the fold changes of a large set of viral and 
cellular proteins tend to be larger in the label-free method. This ratio compression issue has 
been noticed before in less complex samples than used in this study [19, 22, 51-53]. In our case, 
we have validated the results for four proteins by Western blotting (Gal1, Gal3, AG2 and CD98), 
and confirmed that the ratios determined by the label-free method were closer to the values from 
the Western blot analyses than the iTRAQ- ratios.  
 
Advantages and drawbacks of quantitative proteomics using iTRAQ and label-free 
methods  
The findings that the label-free method provided a high dynamic range and was closer to the 
data from Western blotting than the iTRAQ-label approach is important for studies that aim to 
provide high accuracies of protein ratios for different samples. The observation of 
underestimation of protein ratios by iTRAQ is in agreement with previous observations [19, 22, 
53]. The iTRAQ quantitation method could cause underestimation of the actual fold change by a 
number of reasons. (i), precursor ions with similar masses but from different peptides could be 
selected for the acquisition of CID spectra. This would shift the ratio towards one, and result in 
an underestimation of the quantitation of the peptide of interest identified in the CID spectrum. 
The label-free method does not have this drawback if the LCMS signals are properly aligned. (ii), 
identification and quantitation are based on MS/MS data while other methods rely on both full 
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MS and fragmentation of precursor ions. (iii), iTRAQ reagents can pose problems for certain 
types of mass spectrometers due to the low mass cut-off and impurities [21] which seems to be 
a key factor leading to underestimation of iTRAQ quantitation. (iv), in addition, incompletely 
labeled peptides also contribute to quantitation [20]. Despite recent improvements of iTRAQ 
reporter ion intensity in iTRAQ-8plex compared to iTRAQ-4plex and algorithms in PP software to 
filter out background signals, quantitation based on iTRAQ ratios remains problematic.  
Both iTRAQ-8plex and label-free quantitation show benefits and disadvantages. An advantage 
of the iTRAQ-8plex over the label-free method is the ability to analyze up to 8 samples within a 
single LC-MS/MS experiment, while label-free quantitation requires individual LC-MS/MS 
experiments, and consumes more instrument time. On the other hand, the selection of samples 
to be compared has to be determined upfront, and the extent of multiplexing is limited. 
 
Possible biological significance of the results 
Both the iTRAQ-based and label-free methods allowed us to identify a large number of 
differentially regulated proteins in HAdV-B3- and HAdV-C5-infected human lung carcinoma cells. 
For instance, ferritin light chain (FTL, P02792) was up-regulated 1.6 to 1.65 log2 fold in HAdV-B3 
and 2.13 to 2.45 log2 fold in HAdV-C5 with PP or Sc+, respectively (STable 2). FTL plays an 
important role in iron homeostasis and maintenance of iron ions in cells [54]. Another example is 
ITGB5 also known as β5 integrin (P18084), which was down-regulated by 0.6 to 0.75 log2 fold in 
both HAdV-B3- and HAdV-C5-infected cells. ITGB5 belongs to the heterodimeric integrin protein 
family, and αvβ5 integrin functions as a receptor for fibronectin [55] and vitronectin [56]. Both, 
αvβ3 and αvβ5 integrins together with CAR are co-receptors for HAdV-B3 and HAdV-C5 
infections [40, 57-63]. In polarized human epithelial cells, αvβ3 is recruited from the basolateral 
to the apical side upon cytokine stimulation and facilitates apical infection with HAdV-C5 or 
HAdV-C2 [41]. In addition, high expression of ITGB5 is required for efficient HAdV-mediated 
gene transfer in the human airway cells [64].  
Furthermore, Gal1 and Gal3 were both down-regulated in HAdV-B3-infected cells, and to a 
much lesser extent in HAdV-C5-infected cells.  Gal1 and Gal3 are lectins which are involved in 
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intracellular and extracellular signaling [49, 65]. Gal1 interacts with cytoplasmic and nuclear 
proteins to trigger multiple signaling pathways [66], and it is translocated by non-conventional 
mechanisms outside the cell where it binds cell surface glycoproteins and extracellular matrix 
components.  
In addition, Gal1 is involved in infection with Nipah virus [67] and human immunodeficiency virus 
(HIV) [68]. In the case of Nipah virus, Gal1 inhibits virus attachment and host cell fusion by 
binding N-linked oligosaccharides from the virion envelope or capsid glycoproteins, and 
promotes their crosslinking and oligomerization. It promotes HIV infection by stabilizing virus 
attachment to host cells. The role for Gal1 and Gal3 in HAdV infections remains unknown. Thus, 
our finding that down-regulation of Gal1 and Gal3 occurs in HAdV-infected cells 24 h post 
infection suggests a function of these proteins at mid or late stages of infection.  
Other proteins such as AG2, CD98 and immune modifier peptide thymosin alpha 1 (P06454, 
STable2) were found to be down-regulated in HAdV-B3-infected cells by both the iTRAQ-label 
and label-free approaches. AG2 expression levels were found to inversely correlate to p53 
response in the preneoplastic tissue Barrett's oesophagus [69]. CD98 interacts with β1 integrins 
resulting in an increase in its affinity for integrin ligands [70]. Thymosin alpha 1 has been 
clinically tested in combination with other drugs to confer resistance to certain infectious agents 
such as hepatitis B virus [71]. The regulation of thymosin alpha 1 upon HAdV infections may be 
interesting for improvement of gene therapy efforts.   
We also observed a number of proteins with different regulation patterns between HAdV-B3- 
and HAdV-C5-infected cells. These differences could be due to the infectious pathways used by 
these viruses. For instance, heterogeneous nuclear ribonucleoprotein H3 (HNRNPH3, P31942), 
which is involved in early heat shock-induced splicing arrest [72], was down-regulated in HAdV-
B3- (-0.85 log2 ratio) and up-regulated in HAdV-C5-infected cells (0.62 log2 ratio). Similarly 
thioredoxin domain-containing protein 17 (TXNDC17, Q9BRA2), which modulates tissue 
necrosis factor (TNF)-alpha signaling and NF-kappa-B activation [73], was down-regulated in 
HAdV-B3- (-1.25 log2 ratio) and up-regulated in HAdV-C5-infected cells (0.7 log2 ratio). It has 
been shown previously that HAdV-2C E3-19 K protein activated the transcription factor NF-
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kappa-B [74]. Thus, the deregulation of TXNDC17 may be the result of a HAdV serotype-specific 
antiviral response.  
Overall, our findings provide a large set of proteins differentially regulated in the course of HAdV 
infections. This provides a basis for follow-up studies on the mechanisms by which proteins are 
involved in interactions of HAdV with host epithelial cells.  
 
Conclusions 
In this study, we addressed an ongoing controversy about the most suitable methods for 
quantitative proteomics. We measured the relative abundance of a large number of proteins in 
HAdV-infected and non-infected human epithelial A549 cells using two distinct approaches, 
iTRAQ-based quantitation and a label-free method. In addition, we employed two independent 
quantitation software for each quantitation approach to reduce the bias of quantitation. The 
different software for the same dataset resulted in the comparable fold changes or regulation 
patterns. Both methods reliably determined the trends of protein up- or down-regulation in virus-
infected cells with overall technical replica correlation coefficients R2 from 0.48 to 0.86. We 
found that the label-free method had a higher dynamic range and seemed to be more accurate 
than iTRAQ, which tended to underestimate the actual abundance changes of proteins. This 
finding was confirmed by Western blotting for four proteins down-regulated particularly strongly 
in HAdV-B3-infected cells, Gal1, Gal3, AG2 and CD98. However, the iTRAQ approach allowed 
identification and quantification of a much larger number of proteins. The results suggest that the 
label-free method can be used as a rather accurate measure of relative protein abundance in 
complex mixtures of proteins. These analyses provide a basis for deeper studies of cellular and 
viral factors controlling virus-host interactions.  
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Abbreviations  
ACN: acetonitrile 
CID: collision-induced dissociation 
DIGE: differential gel electrophoresis 
HAdV-B3: human adenovirus type 3 
HAdV-C5: human adenovirus type 5 
HPLC: high-performance liquid chromatography 
ICAT: isotope-coded affinity tag 
iTRAQ: isobaric tag for relative and absolute quantitation 
LC: liquid chromatography 
LC-MS: liquid chromatography mass spectrometry 
MALDI-TOF/TOF: matrix-assisted laser desorption/ionization-time of flight 
MMTS: methyl-methanethiosulfonate 
MOI: multiplicity of infection 
MS: mass spectrometry 
PAGE:  polyacrylamide gel electrophoresis 
PBS: phosphate-buffered saline 
PF2: ProgenesisF-T2PQ 
PF3: ProgenesisF-T3PQ 
p.i.: post infection 
PL: Progenesis LC-MS 
PP: ProteinPilot 
Ppm: parts per million 
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RP: reverse phase 
Sc+: ScaffoldQ+ 
SCX: strong cation exchange chromatography 
SDS: sodium dodecyl sulfate 
SILAC: stable isotope labeled amino acids 
T2PQ: top 2 protein quantitation 
T3PQ: top 3 protein quantitation 
TandTRAQ: i-Tracker, an open-source iTRAQ quantitation 
TCA: trichloroacetic acid 
TCEP: Tris[2-carboxyethyl] phosphine 
FDR: false discovery rate 
TFA: trifluoroacetic acid  
TNPQ: Top N protein quantification. 
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Legends to figures  
Figure 1 Workflow for comparisons of iTRAQ-label and label-free quantitations. A549 cell 
lysates were harvested 24 h post infection (p.i.), and proteins were precipitated by TCA, followed 
by trypsin digestion. For the iTRAQ-label approach, the tryptic peptides were labeled with 
iTRAQ-8plex reagents. These included biological replicates for non-infected cells (reporter 113 
and 114), for HAdV-B3-infected cells (reporter 115 and 116), for HAdV-C5-infected cells 
(reporter 117 and 118), and for HAdV-B35-infected cells (reporter 119 and 121, not shown 
here). Peptides were separated by SCX chromatography following RP chromatography and 
spotted onto MALDI plates. The mass spectrometric analyses were performed on the MALDI-
TOF/TOF instrument. Protein quantitation based on iTRAQ data was performed with PP and 
Sc+ software. For the label-free approach, protein digests were analyzed with LC-MS/MS 
without pre-fractionation. The obtained data was quantified by using PL and PF2 and PF3.  
Figure 2 Reproducibility of two independent biological replicates using either iTRAQ-label or 
label-free method and comparison within the iTRAQ-label or label-free with different quantitation 
software. Different expression of proteins in HAdV-B3-infected cells (red) and HAdV-C5-infected 
cells (black) is shown based on log2 ratio. For the iTRAQ-label approach, Scatter plots for 
quantified proteins were analyzed by PP (A), and Sc+ (B), and comparison of software included 
PP vs Sc+ (C). For the label-free approach, Scatter plots for quantified proteins were analyzed 
by PL (D), and by PF2 (E), and comparison of software included PL vs PF2 (F). For 
comparisons in (C) and (F), both biological replicates were used. 
Figure 3 Comparisons of iTRAQ-label-based versus label-free quantitation. All four comparisons 
are given by log2 ratios with HAdV-B3-infected cells (red) and HAdV-C5-infected cells (black). 
Scatter plot analysis for quantified proteins was performed by PP vs PL (A), PP vs PF2 (B), Sc+ 
vs PL (C), and Sc+ vs PF2 (D). As in Fig. 2, both biological replicates were used. 
Figure 4 Comparison of iTRAQ-label-based vs label-free quantitations for virus-induced protein 
expression changes. The iTRAQ-label was based on PP and Sc+ quantitation software, while 
label-free was based on PL and PF2 quantitation software. The threshold of listed proteins was 
set at 0.6 log2 ratio cut-off, and included quantified viral proteins detected in HAdV-B3-infected 
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cells (A), HAdV-C5-infected cells (B), and quantified cellular proteins detected in HAdV-B3-
infected cells (C). Names of HAdV-B3 proteins, most HAdV-C5 proteins and cellular proteins 
correspond to accession names used in the uniprot.org database, except pTP of HAdV-C5 
which was obtained from NCBI database (uniprot database does not contain this protein 
sequence), denoted as (**). (*) indicates that no quantitation value was obtained. 
Figure 5 Expression analysis of five cellular proteins and comparison of different quantitation 
methods. Lysates from Ctrl (non-infected cells), and HAdV-B3/C5-infected A549 cells (biological 
duplicates) were used for Western blot analyses. Alpha-tubulin was used as a loading control for 
the normalization. Western blot analyses and quantitative comparisons were performed for Gal1 
(LEG1_HUMAN) (A), Gal3 (LEG3_HUMAN) (B), AG2 (AGR2_HUAMN) (C), and CD98 
(4F2_HUMAN) (D).  nq: no quantitation value was obtained.  
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Table 1.  Number of proteins quantified in HAdV-B3 and -C5-infected cells using different 
software packages  
Software package 
Number of quantified 
proteins 
HAdV-B3-infected cells 
Number of quantified 
proteins 
HAdV-C5-infected cells 
ProgenesisF-T3PQ (label-free) 347 347 
ProgenesisF-T2PQ (label-free) 438 438 
Progenesis LC-MS (label-free) 660 661 
ProteinPilot (iTRAQ data) 1,548 1,538 
ScaffoldQ+ (iTRAQ data) 1,343 1,340 
 
Table 2. Number of proteins commonly quantified with pairs of software packages 
Software packages 
Number of quantified 
proteins 
HAdV-B3-infected cells 
Number of quantified 
proteins 
HAdV-C5-infected cells 
ProgenesisF-T2PQ vs Progenesis LC-MS 438 438 
ProgenesisF-T2PQ vs ProgenesisF-T3PQ 347 347 
ProteinPilot vs ProgenesisF-T2PQ 406 410 
ProteinPilot vs Progenesis LC-MS 569 564 
ScaffoldQ+ vs ProgenesisF-T2PQ 396 394 
ScaffoldQ+ vs Progenesis LC-MS 535 532 
ScaffoldQ+ vs ProteinPilot 1,267 1,263 
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Additional files 
SFigure 1 Comparison of PF2 and PF3 for label-free quantitations. Samples were obtained from 
HAdV-B3-infected cells (red), and HAdV-C5-infected cells (black). 
 
STable 1 Pairwise comparisons for commonly quantified proteins given by log2 ratios. The ratios 
for the same proteins in HAdV-B3/C5-infected cells vs Ctrl were compared by different 
quantitation software including PL vs PP (581 proteins), PL vs Sc+ (540 proteins), PF2 vs PL 
(455 proteins), PF2 vs PF3 (363 proteins), PF2 vs PP (442 proteins), and PF2 vs Sc+ (1,673 
proteins). (*) indicates the value derived from the quantitation software which is used for 
comparison. For example, PL vs PP*, (*) indicates the values of quantitation obtained from the 
PP quantitation software. 
 
STable 2 List of significantly up- or down-regulated viral and cellular proteins quantified by 
iTRAQ and by label-free methods. Proteins with significant (Sig) fold changes higher than 0.6 
log2 ratio are shown in bold. Viral proteins encoded by HAdV-B3 and HAdV-C5 appear in red 
and blue, respectively; cellular proteins appear in black. 
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